PerkinElmer: AlphaLISA KRAS kits
PerkinElmer has launched four ready-to-use AlphaLISA kits, intended to help researchers better understand complex KRAS protein structures and mutations. The technology is geared toward enabling scientists to quickly and precisely identify potential therapeutic candidates for various cancers.
Alan Fletcher, senior vice president of life sciences and technology at PerkinElmer, said, “Because KRAS mutations are found in numerous types of cancer, from lung to colorectal to pancreatic cancers, it’s a prime drug target; however, due to its complex protein structure, it’s been quite difficult to research for many years. We’re proud to help advance opportunities for researchers to learn more about KRAS mutations in the hopes of providing better treatment opportunities by bringing our AlphaLISA kits to market in this critical research space.”